Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Min

Showing results (271-280 of 278) with videos related to

Pageof 28
Sort By:
You have reached the last page of results.This site can display upto 278 results.
Diabetes, Obesity & Metabolism|January 13, 2015
Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extensionS-M Jin, C-Y Park, Y M Cho, et al.
Diabetes, Obesity & Metabolism|December 20, 2014
Anagliptin and sitagliptin as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, active-controlled, phase III clinical trial with a 28-week extensionS-M Jin, S W Park, K-H Yoon, et al.
Diabetes, Obesity & Metabolism|November 23, 2012
A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetesS J Yang, K W Min, S K Gupta, et al.
Oncogene|April 23, 2013
The role of DAB2IP in androgen receptor activation during prostate cancer progressionK Wu, J Liu, S-F Tseng, et al.
International Journal of Clinical Practice|January 23, 2013
Efficacy and safety of glimepiride/metformin sustained release once daily vs. glimepiride/metformin twice daily in patients with type 2 diabetesY-C Hwang, M Kang, C W Ahn, et al.
Diabetes, Obesity & Metabolism|October 28, 2010
A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetesE J Rhee, W Y Lee, K H Yoon, et al.
Nature Genetics|September 6, 2000
Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body massA S Chen, D J Marsh, M E Trumbauer, et al.
Optics Express|February 8, 2013
Slewing Mirror Telescope optics for the early observation of UV/optical photons from Gamma-Ray BurstsS Jeong, J W Nam, K B Ahn, et al.
Pageof 28

Showing results (271-280 of 278) with videos related to

Sort By:
Pageof 28
You have reached the last page of results.This site can display upto 278 results.
Diabetes, Obesity & Metabolism|January 13, 2015
Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extensionS-M Jin, C-Y Park, Y M Cho, et al.
Diabetes, Obesity & Metabolism|December 20, 2014
Anagliptin and sitagliptin as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, active-controlled, phase III clinical trial with a 28-week extensionS-M Jin, S W Park, K-H Yoon, et al.
Diabetes, Obesity & Metabolism|November 23, 2012
A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetesS J Yang, K W Min, S K Gupta, et al.
Oncogene|April 23, 2013
The role of DAB2IP in androgen receptor activation during prostate cancer progressionK Wu, J Liu, S-F Tseng, et al.
International Journal of Clinical Practice|January 23, 2013
Efficacy and safety of glimepiride/metformin sustained release once daily vs. glimepiride/metformin twice daily in patients with type 2 diabetesY-C Hwang, M Kang, C W Ahn, et al.
Diabetes, Obesity & Metabolism|October 28, 2010
A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetesE J Rhee, W Y Lee, K H Yoon, et al.
Nature Genetics|September 6, 2000
Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body massA S Chen, D J Marsh, M E Trumbauer, et al.
Optics Express|February 8, 2013
Slewing Mirror Telescope optics for the early observation of UV/optical photons from Gamma-Ray BurstsS Jeong, J W Nam, K B Ahn, et al.
Pageof 28